September 3, 2024 01:22 PM EDTUpdated 03:59 PM
Pharma
FDA+

Eu­ro­pean Com­mis­sion re­vokes Ocali­va's au­tho­riza­tion ahead of FDA ad­comm

Katherine Lewin

News Reporter

Ad­vanz Phar­ma on Tues­day said its liv­er dis­ease treat­ment Ocali­va suf­fered a set­back as the Eu­ro­pean Com­mis­sion re­voked its con­di­tion­al mar­ket­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times